skip to Global Navigation Bar skip to main content

homeHome > About Us > Press Release > News


News Content
Daewoong Pharmaceutical enters into new drug candidate ‘BBT-401’ joint development and technology transfer contract with Bridgebio
Date 2018-12-19 Hit 1818
News List
Prev Daewoong Pharmaceutical attended ICAD 2018 and promoted benefit of Nabota
Next Daewoong Pharmaceutical’s ‘NABOTA’ becomes the first Korea-made Botulinum Toxin to obtain US FDA approval